|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
36,440,000 |
Market
Cap: |
347.64(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$9.54 - $9.54 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile SeaSpine Holdings is a medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. Co. has a portfolio of orthobiologics and spinal implant solutions, as well as a surgical navigation system to perform fusion procedures in the lumbar, thoracic and cervical spine. Co.'s orthobiologics products consist of a range of bone graft substitutes including spine, hip, and extremities procedures. Co.'s spinal implants portfolio consists of a line of products and image-guided surgical solutions to help spinal fusion in degenerative, minimally invasive surgery, and spinal deformity procedures.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
3,786 |
Total Sell Value |
$0 |
$0 |
$0 |
$30,288 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-06-20 |
2024-03-19 |
2023-09-19 |
2022-09-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Valentine Keith |
Chief Executive Officer |
|
2019-01-01 |
4 |
D |
$18.24 |
$430,665 |
D/D |
(23,611) |
224,031 |
|
- |
|
Valentine Keith |
Chief Executive Officer |
|
2019-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,366 |
247,642 |
|
- |
|
Bostjancic John J. |
Chief Financial Officer |
|
2019-01-01 |
4 |
D |
$18.24 |
$185,027 |
D/D |
(10,144) |
66,694 |
|
- |
|
Bostjancic John J. |
Chief Financial Officer |
|
2019-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,123 |
76,838 |
|
- |
|
Lipschultz Tyler |
SVP, Orthobiologics and BD |
|
2019-01-01 |
4 |
D |
$18.24 |
$85,017 |
D/D |
(4,661) |
72,973 |
|
- |
|
Lipschultz Tyler |
SVP, Orthobiologics and BD |
|
2019-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,123 |
77,634 |
|
- |
|
Winge John J. |
Vice President, Sales |
|
2018-12-31 |
4 |
A |
$6.43 |
$9,922 |
D/D |
1,544 |
32,646 |
|
- |
|
Keran Patrick L |
VP, General Counsel |
|
2018-12-31 |
4 |
A |
$6.43 |
$7,210 |
D/D |
1,122 |
26,127 |
|
- |
|
Valentine Keith |
Chief Executive Officer |
|
2018-12-31 |
4 |
A |
$6.43 |
$7,750 |
D/D |
1,206 |
184,276 |
|
- |
|
Lipschultz Tyler |
SVP, Orthobiologics and BD |
|
2018-12-31 |
4 |
A |
$6.43 |
$6,722 |
D/D |
1,046 |
49,511 |
|
- |
|
Bradley Keith |
Director |
|
2018-11-30 |
4 |
D |
$19.66 |
$983 |
D/D |
(50) |
40,908 |
|
- |
|
Bradley Keith |
Director |
|
2018-08-30 |
4 |
D |
$14.87 |
$744 |
D/D |
(50) |
40,958 |
|
- |
|
Henneman John B III |
Director |
|
2018-08-29 |
4 |
S |
$14.65 |
$49,913 |
D/D |
(3,407) |
54,708 |
|
- |
|
Henneman John B III |
Director |
|
2018-08-28 |
4 |
S |
$14.65 |
$29,725 |
D/D |
(2,029) |
58,115 |
|
- |
|
Henneman John B III |
Director |
|
2018-08-27 |
4 |
S |
$14.72 |
$67,182 |
D/D |
(4,564) |
60,144 |
|
- |
|
Essig Stuart |
Director |
|
2018-08-02 |
4 |
S |
$14.00 |
$608,944 |
D/D |
(43,496) |
414,929 |
|
- |
|
Essig Stuart |
Director |
|
2018-08-02 |
4 |
OE |
$13.60 |
$591,546 |
D/D |
43,496 |
458,425 |
|
- |
|
Winge John J. |
Vice President, Sales |
|
2018-06-29 |
4 |
A |
$6.43 |
$11,329 |
D/D |
1,763 |
31,102 |
|
- |
|
Keran Patrick L |
VP, General Counsel |
|
2018-06-29 |
4 |
A |
$6.43 |
$14,041 |
D/D |
2,185 |
25,005 |
|
- |
|
Valentine Keith |
Chief Executive Officer |
|
2018-06-29 |
4 |
A |
$6.43 |
$13,501 |
D/D |
2,101 |
183,070 |
|
- |
|
Lipschultz Tyler |
SVP, Orthobiologics and BD |
|
2018-06-29 |
4 |
A |
$6.43 |
$14,529 |
D/D |
2,261 |
48,465 |
|
- |
|
Bradley Keith |
Director |
|
2018-06-14 |
4 |
D |
$14.03 |
$2,399 |
D/D |
(171) |
41,008 |
|
- |
|
Henneman John B III |
Director |
|
2018-06-13 |
4 |
OE |
$12.44 |
$216,431 |
D/D |
17,398 |
64,708 |
|
- |
|
Blanchard Cheryl R |
Director |
|
2018-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,857 |
28,948 |
|
- |
|
Henneman John B III |
Director |
|
2018-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
13,286 |
47,310 |
|
- |
|
328 Records found
|
|
Page 9 of 14 |
|
|